Format

Send to

Choose Destination
J Microbiol Methods. 2017 May;136:11-16. doi: 10.1016/j.mimet.2017.02.013. Epub 2017 Mar 1.

Evaluation of a serological test for the diagnosis of Borrelia miyamotoi disease in Europe.

Author information

1
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: seta.Jahfari@rivm.nl.
2
Izhevsk State Medical Academy, Kommunarov 281, 426034 Izhevsk, Udmurtskaja Respublika, Russia. Electronic address: bizi1973@gmail.com.
3
Central Research Institute of Epidemiology, Moscow, Russia. Electronic address: kolyasnikova@cmd.su.
4
Department of Internal Medicine, Section of Infectious Diseases, Academic Medical Centre, Amsterdam, The Netherlands. Electronic address: J.W.Hovius@amc.uva.nl.
5
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: hein.Sprong@rivm.nl.
6
Central Research Institute of Epidemiology, Moscow, Russia. Electronic address: platonov@pcr.ru.

Abstract

BACKGROUND:

Borrelia miyamotoi causes systemic febrile illness and is transmitted by the same tick species that transmits Borrelia burgdorferi sensu lato and tick-borne encephalitis virus. We describe a serological test using a fragment of glycerophosphodiester phosphodiesterase (GlpQ) as an antigen, and determined its performance in well-defined patient categories.

METHODS:

Serum of patients with PCR-confirmed Borrelia miyamotoi disease (BMD), Lyme borreliosis (LB), tick-borne encephalitis (TBE), and healthy blood donors (HBD) were collected in Udmurt Republic, Russia. Sera of BMD and LB patients were collected at hospital admission, one week, one month and one year after admission.

RESULTS:

The levels of IgM and IgG anti-GlpQ antibodies, determined as optical density values in Luminex bead-based assays, were significantly higher in the BMD patient group than in LB patients, TBE patients or HBD group (all p<0.05).

CONCLUSIONS:

By using a strict cut-off value, it was possible to exclude B. miyamotoi infection in LB and TBE patients and to serologically confirm B. miyamotoi infection in 44% to 94% of the PCR-positive BMD patients (95% confidence interval). Thus, sensitive serological assays should not solely rely on rGlpQ, to support the diagnosis of acute BMD.

KEYWORDS:

Borrelia miyamotoi; Diagnosis; Human relapsing fever borreliosis; Tick-borne disease; Validation

PMID:
28259789
DOI:
10.1016/j.mimet.2017.02.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center